Reversible epigenetic alterations regulate class I HLA loss in prostate cancer
Tamara S. Rodems(Therapeutics Clinical Research), Joshua M. Lang(University of Wisconsin–Madison)
Cited by 52
Related Papers
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
|Annals of Oncology|2021|371
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
|PubMed|2022|172
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
|Clinical Cancer Research|2023|52